(Date:5/13/2008)... Calif., May 13 /PRNewswire/ -- Personalized medic... pharmacogenomic tests can help,physicians determi...edict,the potential for adverse drug reactions. In...ge protein-based biomarkers to predict drug safety...gulex Inc., a company focused on advancing technol...
(Date:5/13/2008)...es JMR,s BlueStor Storage Array to boost post prod...CHATSWORTH, Calif., May 13 /PRNewswire/ -- JMR Ele...upplier of Storage and Server Platforms,for OEMs, ... its,BlueStor(TM) External PCIe RAID Storage Syste...eyShed ( http://www.honeyshed.com ) as part of the...
(Date:5/13/2008)... of the blood-pressure drugs given in the study we... (HealthDay News) -- Patients who received the blo...after having non-cardiac surgery were at higher ri...dy found. , However, the patients receiving the...ck, according to the report in the May 13 online i...
(Date:5/13/2008)...y 13 /PRNewswire-USNewswire/ -- Donnie Lawless may...uction company promoter, but he,still has a pretty...isabilities - not exactly what you,d expect from a...ith the Hard Rock Cafe at Station Square,Lawless ...ns have planned,Pittsburgh,s first annual Rock for...
Breaking Medicine News(10 mins):Health News:Singulex Advances Conversation on Personalized Medicine 2Health News:JMR Electronics BlueStor(TM) Storage Array Empowers HoneyShed's Post Production Process 2Health News:JMR Electronics BlueStor(TM) Storage Array Empowers HoneyShed's Post Production Process 3Health News:JMR Electronics BlueStor(TM) Storage Array Empowers HoneyShed's Post Production Process 4Health News:Beta Blockers Raise Stroke, Death Risk After Surgery 2Health News:Beta Blockers Raise Stroke, Death Risk After Surgery 3Health News:Rockin' Out for Autism in Pittsburgh 2...7 times? In a pathetic culmination of a young fath...dren, died due to cancer of the kidney, after doc...nce or twice, but 37 times. // Peter Cura, a carp... many times over the last14 month period after suf...
...st medical experiment at Altrincham, Cheshire. // ...o the first set of participants. The main aim of t... and treatment of cancer, heart disease, diabetes,...ny other serious illnesses. It also plans to rev...
...22,000 people over the span of five years. They st...e of the vegetarians. // Professor Tim Key said t...tch to a meat-free diet. He is currently working ...ch UK charity and the University of Oxford. Scient...
...munity service dedicated to the mentally ill. Fou... assistance to mentally ill and their families.// ...ation, Bluegrass Impact South and the Learning Gar...grass Regional Mental Health/Mental Retardation Bo...
Other Medicine News:Health News:37 times unlucky – Failure to Diagnose Cancer, Takes the Life of a 31 year old fathe 2Health News:UK Biobank Set Up To Understand the Links between Genes, Lifestyle Environment and Illness 2(Date:5/12/2008)...re-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin B...velopment,company, announced today that it has ent...ement with Fusion Capital Fund II, LLC, a Chicago-...ll up to $10 million of its common stock to Fusion...after the Securities and,Exchange Commission has d...
(Date:5/12/2008)...ination of Scaffolding, Deliverability and ...rael, May 12 /- Medinol is proud to a...llion(TM) CoCr Coronary Stent,enabling physicians...ically,innovative flexible closed cell design sten...ng the unprecedented,balance of flexibility and co...
(Date:5/12/2008)...ewswire-USNewswire/ -- GlaxoSmithKline (GSK),in c...BIG), a leading,academic breast cancer research ne...reast Cancer Cooperative Group (SOLTI), today anno...ill examine the role of TYKERB(R) in the,treatment...patinib and/or,Trastuzumab Treatment Optimization)...
(Date:5/9/2008)...wire-USNewswire/ -- Osteoarthritis is a,painful an...almost 50,million people in the United States. It ...ints. The novel investigational pain medication,ta...ded significant relief,for patients with joint-dis... and with fewer gastrointestinal side effects than...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 1Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 3Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 1Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 2Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 3Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 4Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 5Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 1Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 2Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 3Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 1Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 17...007 /PRNewswire/ -- Berlex, Inc., a U.S.,affiliate...oday the,results of a retrospective study demonstr... (NAbs) that can develop in response to,Betaseron(...inical,response in patients with multiple sclerosi...0 patients across three continents. It,is the larg...
...SINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics In...S.,Phase 2 study of Proellex(TM), an oral drug bei...ds. This study suggests that,treatment with Proell...mprovement in symptoms associated with uterine,fib...ils and Results , This 12 week, double-blind study...
Other Medicine Technology:Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 2Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 3Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases.
Passive heat and moisture exchangers for respiratory applications.
Medicine Products: